国内医疗器械"一哥"迈瑞医疗（300760.SZ）正在经历增长换档阶段。 2024年开始，迈瑞医疗结束持续多年的高增长。2017年到2022年，迈瑞医疗营收同比增速均保持在20% 以上，营收体量也远高于国内同行；2023年营收增速虽有所放缓，但仍实现15%以上的增长。而2016年 至2023年，迈瑞每年净利润增速均超过20%。 2024年，迈瑞医疗营收和净利润增速均放缓至个位数；2025年上半年，迈瑞营收为167.43亿元，同比下 降18.45%；归属于上市公司股东的净利润为50.69亿元，同比下降32.96%。 迈瑞的业绩表现在一定程度上与行业环境变化有关：国内医疗器械行业或已从过去十多年的高增长进入 相对平稳的增长阶段。 在存量市场的竞争中，即便是行业老大哥，迈瑞也不得不时常大幅降价以守住市场份额。 根据媒体报道，今年1月，江西省医保局公布糖代谢等生化类检测试剂省际联盟集中带量采购中选结 果，共有154家企业的2314个规格中选，产品价格平均降幅70%。多家企业报价均低于1毛钱，其中罗 氏、贝克曼、西门子、迈瑞和新产业的"离子微量元素|钙（CA）"产品均以0.07元/人份的价格中选。 迈瑞业绩承压之际，今 ...

Group 1 - The core project "Research on Lipoprotein Profile and New Intervention Targets Based on Large Natural Population Cohorts" has been officially approved, aiming to address residual risk in atherosclerotic cardiovascular diseases using VAP precision lipid testing technology [1] - VAP precision lipid testing technology utilizes vertical density gradient centrifugation to quantitatively measure major components and subcomponents of lipoproteins in human serum or plasma, providing significant value in risk prediction and individualized treatment for cardiovascular diseases [1] - The company has obtained Class II medical device registration for VAP-related reagents and instruments, and its testing methods have been included in national clinical guidelines, enhancing market recognition and clinical application of precision lipid products [1] Group 2 - The company has over 20 years of experience in the IVD industry, with a comprehensive product line covering various technology platforms, making it one of the most complete and diverse IVD manufacturers in China [2] - The strategic layout of the company focuses on the synergy of diagnostic instruments, core diagnostic products, and diagnostic services, supported by multiple R&D centers and collaborations with universities and research institutions [2] - As of the end of 2024, the company has obtained 49 diagnostic instrument registration certificates and 459 supporting reagent registration certificates, covering essential equipment for various diagnostic needs [2] Group 3 - The company is the first Chinese IVD manufacturer to join JCTLM, promoting standardization and global recognition of test results, and has participated in the development of over 30 international and national standard materials [3] - The collaboration with Peking University First Hospital on the national major science and technology project signifies a breakthrough in the integration of industry, academia, and research [3] - The company plans to increase R&D investment and deepen technological innovation, aiming to contribute to chronic disease management and prevention in alignment with the "Healthy China 2030" strategy [3]

Core Insights - Chengdu Eastern New Area has achieved significant development in its first five years, with a focus on high-quality growth and innovation [16][20][21] - The region has established itself as a hub for advanced manufacturing, biotechnology, and smart city initiatives, attracting numerous projects and investments [4][5][8][18] Group 1: Economic Development - The region's GDP reached 32.26 billion yuan in 2024, a 2.5 times increase since its establishment, with an 11% growth rate, the highest in Chengdu [16][17] - Chengdu Eastern New Area has introduced 28 industrialization projects and registered 61 companies, showcasing its commitment to fostering a robust industrial ecosystem [3][5] - The area has implemented 146 key projects with a total investment of 43.176 billion yuan, focusing on advanced manufacturing [17][18] Group 2: Innovation and Technology - The establishment of the Chengdu Jiaozi Zhongying Fund, with a total scale of 5 billion yuan, aims to create a comprehensive financial service system for innovation [7] - The region has introduced a "smart project management service system" to enhance project approval efficiency and inter-departmental collaboration [9][20] - Chengdu Eastern New Area has been recognized as a leading area for innovation, ranking first in the "Top 100 Urban New Area Development Potential" list for three consecutive years [18] Group 3: Infrastructure and Public Services - The transportation network has been significantly improved, with the completion of multiple rail and road projects, enhancing connectivity within the region [13] - The area has opened 23 new schools and kindergartens, adding over 25,130 educational slots to meet the growing demand for quality education [14] - Healthcare facilities are expanding, with the opening of new hospitals and partnerships to enhance medical services [14][15] Group 4: Future Outlook - Chengdu Eastern New Area aims to attract high-quality industrial projects by focusing on six categories of Fortune 500 companies and industry leaders [8] - The region is set to establish a modern industrial system by 2030, emphasizing strategic emerging industries and modern services [8][12] - The area is positioned to become a significant player in the Chengdu-Chongqing economic circle, contributing to the broader economic landscape of the region [20][21]

导读： 近日，昆明医科大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出10项仪器设备采购意向，预算总额达8332万 | 采购 | | 预算 | 采购 | | --- | --- | --- | --- | | 项目 | 需求概况 | 万元 | 时间 | | 教学科研 | | | | | 大型仪器 | | | | | 设备更新 | 为提高学校教学、科研能力，自筹经费更新一批实验室设 | 7100 | 2025年 | | 采购项目 | 备。 | | 2月 | | （自筹经 | | | | | 费） | | | | | 康复学院 | | | | | 省一流学 | | | 2025年 | | 科建设设 | 满足学校教学及科研需求。 | 292 | 5月 | | 备采购项 | | | | | 目 | | | | | 康复学院 | | | | | 智慧教室 | | | 2025年 | | 设备采购 | 满足学校教学及科研需求。 | 100 | 5月 | | 项目 | | | | | 基础医学 | | | | | 院一流学 | | | | | 科团队平 | 设备仪器一批. | 92 | 2025年 ...